Tracking Innovation in Drug Delivery at CPhI

Innovation is the cornerstone of the pharmaceutical industry. That innovation is not only seen in new drug development but also in approaches to extend the lifecycle of a given product through improved formulations and drug-delivery systems. Recent advances and trends in drug-delivery systems were highlighted at one of the sessions at the Pre-Connect Conference held at CPhI Worldwide in Madrid this week. Read more »

Silk Protein Preserves Drugs Without Refrigeration

Tufts University research shows that silk protein can be used to stabilize and maintain the potency of vaccines and other drugs that would otherwise need refrigeration. “Silk stabilization has the potential to significantly change the way we store and deliver pharmaceuticals, especially in the developing world,” said research-paper author and Tufts doctoral student, Jeney Zhang, in a press release. Read more »

Bright Future, Big Molecules

Erik Greb PharmTech editor

The patent cliff is beginning to reduce Big Pharma’s sales figures as generic versions of branded drugs enter the market. Although FDA has remarked that pharmaceutical innovation is beginning to increase, not all companies are going to be able to market enough new drugs to make up for lost sales. So how will these vulnerable companies maintain their profits? Read more »

Georgia Researchers Develop Multicompartment Gel Capsules

Erik Greb PharmTech editorA dosage form that delivers several drugs, either at once or in succession, can have many benefits for patients. The administered drugs could have synergistic effects when delivered together, and the convenient dosage form could improve patient compliance. And, of course, reformulating several drugs for codelivery could help breathe new life into a company’s patents. All of these advantages came to mind when I learned about a multiple-compartment gel capsule developed at the Georgia Institute of Technology. Read more »

Magnetic Pills A Sign Of The Future?

Stephanie Sutton Pharm Tech EuropeInnovative research is constantly being carried out in the pharma industry so it’s easy to start letting your eyes glide over some of the developments taking place. This week though a lot of eyes have been pulled to a study involving magnetically controlled pills. Many people would rather take drugs orally than via injection, but tablets do not always dissolve at exactly the right site in the gastrointestinal (GI) tract for absorption into the bloodstream. Magnetically-controlled pills, however, enable a tablet to be held in place at the correct site in the GI tract to optimize absorption. Read more »

The Future Could Be Needle-Free

Erik Greb PharmTech editorPatients who take biological drugs traditionally have had little choice but to submit to injections. Yet needlephobes should take heart. Several partnerships are developing other ways to deliver large molecules that seem to show promise. Read more »

Industry should consider combination

Stephanie Sutton Pharm Tech EuropeThere has been a surge in the number of combination product (i.e. where a drug product is combined with a medical device) launches in recent years and this trend is set to continue as more companies seek to extend the life of existing branded medicines. According to analysts, the combination product market is currently worth 8 billion Euros and will grow by a staggering 40% during the next 3 years. Read more »

Pharma packs a punch

Fedra Pavlou PharmTech Europe editorI have just returned from an event in France which, I have to say, really impressed me. Not because I had the perfect excuse to visit Paris for a couple of days (although that was undoubtedly a bonus), but because I was so impressed by the calibre of presentations and new innovations that were showcased from this relatively small meeting. Read more »

Do We Need Fresh (Fake) Blood?

Erik Greb PharmTech editorArt imitates life, and sometimes drug-delivery mechanisms do, too. Scientists often draw inspiration from natural agents and the body’s processes when developing carriers for therapies. Synthetic red blood cells are a new product of this strategy that seems to raise new possibilities in drug delivery. Read more »

GSK Wants to Get under Your Skin

Erik Greb PharmTech editorDespite, or because of, economic difficulties and meager pipelines, the recent past has seen many drug companies investigate alternative delivery methods for new and established products. A new deal between GlaxoSmithKline (GSK, London) and Intercell (Vienna) reflects this trend and raises hopes for the development of innovative routes of administration. Read more »

Next Page »